



多発性硬化症治療学講座

メタデータ	言語: Japanese 出版者: 福島県立医科大学附属学術情報センター 公開日: 2023-06-22 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	https://fmu.repo.nii.ac.jp/records/2001429

多発性硬化症治療学講座

論 文

〔原 著〕

Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, MD, Pittock, SJ; PREVENT Study Group. Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. *Annals of Neurology*. 202106; 89(6):1088-1098.

Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, Okita K, Sasou S, Watanabe M, Namatame C, Matsumoto Y, Ono H, Kaneko K, Nishiyama S, Kuroda H, Nakashima I, Lassmann H, Fujihara K, Itoyama Y, Aoki M. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. *Brain*. 202109; 144(8):2401-2415.

Fujimori, Fujihara K, Wattjes M, Nakashima I. Patterns of cortical grey matter thickness reduction in multiple sclerosis. *Brain and Behavior*. 202104; 11(4):e02050.

Akaishi T, Himori N, Takeshita T, Fujihara K, Misu T, Takahashi T, Fujimori J, Ishii T, Aoki M, Nakazawa T, Nakashima I. Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. *Brain and Behavior*. 202105; 11(5):e02083.

Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I. Early Treatment Initiation with Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *Frontiers in Neurology*. 202102; 12:608149.

Namatame C, Misu T, Takai Y, Nishiyama S, Nakashima I, Fujihara K, Aoki M. CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. *Heliyon*. 202101; 7(1):e05899.

Akaish T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishi T, Aoki M, Fujihara K, Nakashima I. Progression pattern of neurological disability in reference to clinical attacks in anti-MOG antibody-associated disorders. *Journal of Neuroimmunology*. 202102; 351:577467.

Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, Haramura M, Palace J, Yamamura T; The Guthy-Jackson Charitable Foundation NMOSD Quality of Life Working Group. Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life. *Journal of the Neurological Sciences*. 202109; 428:117546.

Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ogawa R, Abe M,

Ishii T, Aoki M, Nakashima I. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. *Journal of Neurology*. 202105; 268(5):1938-1944.

Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, Aoki M, Nakashima I. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. *Journal of Neurology*. 202206; 269(6):3136-3146.

Asano T, Saito Y, Matsuo N, Temmoku J, Fujita Y, Hattori K, Kobayashi S, Ojima A, Takahashi T, Matsumoto H, Yashiro-Furuya M, Sato S, Kobayashi H, Watanabe H, Yano K, Sasajima T, Fujihara K, Migita K. Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: a case report. *Medicine*. 202104; 100(15):e24889.

Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. *Multiple Sclerosis*. 202111; 27(13):2052-2061.

Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S; PREVENT Study Group. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial. *Multiple Sclerosis and Related Disorders*. 202101; 47:102641.

Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, Fujihara K, Aoki M. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. *Multiple Sclerosis and Related Disorders*. 202104; 49:102750.

Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. *Multiple Sclerosis and Related Disorders*. 202105; 50:102849.

Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I. Five-year visual outcome after optic neuritis in anti-MOG antibody-associated disease. *Multiple Sclerosis and Related Disorders*. 202111; 56:103222.

Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakashima I. Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. *Neurology*. 202107; 97(1):e1-e12.

Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, EKatz E, Cree BAC; N-MOMentum Study Investigators. Disability outcomes in the N-

MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. *Neurology® Neuroimmunology & Neuroinflammation*. 202103; 8(3):e978.

Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, Takahashi T, Misu T, Takeshita Y, Sano Y, Fujisawa M, Maeda T, Nakashima I, Fujihara K, Kanda T. GRP78 antibodies are associated with blood-brain barrier-breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder. *Neurology® Neuroimmunology & Neuroinflammation*. 202111; 9(1):e1038.

Akaishi T, Misu T, Fujihara K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Takahashi T, Kuroda H, Fujimori J, Takai Y, Nishiyama S, Kaneko K, Ishii T, Aoki M, Nakashima I, Hozawa A. White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments. *Scientific Reports*. 202111; 11(1):22357.

過年業績

Matsumoto Y, Misu T, Mugikura S, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Fujimori J, Nakashima I, Fujihara K, Aoki M. Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases. *Journal of Neurology, Neurosurgery, and Psychiatry*. 202012; 92(6):jnnp-2020-324818.

〔総説等〕

Levy M, Fujihara K, Place J. New therapies for neuromyelitis optica spectrum disorders. *Lancet Neurology*. 202101; 20(1):60-67.

Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Dphil HA, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selma J, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B. Myelin-oligodendrocyte glycoprotein antibody-associated disease. *Lancet Neurology*. 202109; 20(9):762-772.

研究発表等

〔招待講演〕

Fujihara K. Neuromyelitis Optica Spectrum Disorders (NMOSD). 2nd Annual Congress of the Sri Lanka Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS); 20210116-17; Colombo, Sri Lanka.

Fujihara K. Paediatric MOG-antibody-associated disease (MOGAD). 2nd Annual Congress of the Sri Lanka Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS); 20210116-17; Colombo, Sri Lanka.

Fujihara K. Lucky Science. Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2021 (22nd Annual Meeting); 20210609-12; Web.

Fujihara K. Prognostic factors in NMOSD. Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2021 (22nd Annual Meeting); 20210609-12; Web.

Fujihara K. Evolving Classification of NMO & Related Disorders. 8th Mexican Committee for Treatment and Research in Multiple Sclerosis (MEXCTRIMS); 20210619; Web.

Fujihara K. Mimickers and Differential Diagnosis of CNS Inflammatory Diseases. PACTRIMS Pan-Asian Course for Training in MS and Neuroimmunology (PACTMAN) Webinar Series 2; 20210624; Web.

Fujihara K. A 44yo man who had aphasia 5 years after brainstem encephalitis. Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) 2021; 20210727; Web.

Fujihara K. What is new in pathogenesis and treatment of NMOSD. 24th Annual Conference of Chinese Neurological Association; 20210923; Web.

Fujihara K. NMOSD and MOGAD: evolution of the clinical and pathophysiological concepts. VIII Annual Congress of Hungarian Neuroimmunology Society; 20210924; Siofok, Hungary.

Fujihara K. HOW DO I TREAT NEUROMYELITIS OPTICA. 25th World Congress of Neurology; 20211003-07; Web.

Fujihara K. Treating NMOSD. 25th World Congress of Neurology; 20211003-07; Web.

Fujihara K. UPDATE ON TREATMENT OF THE OTHER DEMYELINATING DISEASES. 25th World Congress of Neurology; 20211003-07; Web.

Fujihara K. Personalizing Maintenance Therapy: Factors & Formula. Guthy-Jackson Charitable Foundation Pre-ECTRIMS NMOSD Roundtable Symposium Tuesday; 20211012; Web.

Fujihara K. The evolving landscape in NMOSD management. 37th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS); 20211013-15; Web.

Fujihara K. The power of global scientific collaboration. 37th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS); 20211013-15; Web.

Fujihara K. Treatment targets in NMOSD: a pathophysiological view. 37th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS); 20211113-15; Web.

Fujihara K. Diseases associated with NMO-IgG and MOG-IgG, when to treat? 11th Congress of Latin American committee for Treatment and Research in Multiple Sclerosis (LACTRIMS); 20211109; Web.

Fujihara K. Lessons from experimental studies. 11th Congress of Latin American committee for Treatment and Research in Multiple Sclerosis (LACTRIMS); 20211112; Web.

Fujihara K. Is anti MOG a disease or one of the many variants of MS? 15th Congress of International Society of Neuroimmunology (ISNI); 20211112; Web.

Fujihara K. Neuromyelitis Optica: evolution of the concept and challenges. 29th Annual Meeting of the European Charcot Foundation; 20211114; Baveno, Italy/Web.

Fujihara K. Update on the Treatment of NMO. 6th Congress of Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS); 20211210-11; Dubai, UAE/Web.

低侵襲腫瘍制御学講座

論 文

〔原 著〕

Miyakawa T, Kawamura H, Yamamoto R, Hashimoto K, Kobayashi H, Yue C, Hori S, Hirano T, Honda M. Risk of postoperative urinary retention with early removal of the urinary catheter after surgery with epidural analgesia: A systematic review and meta-analysis. *Annals of Cancer Research and Therapy*. 202107; 29(2):178-187.

Saito SN, Otsuka S, Zenbutsu S, Hori S, Honda M, Nakagawa S. Generation mechanisms of bowel sounds by simultaneous measurements of X-ray fluoroscopy and bowel sounds. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. 202111; 2021:1593-1596.

Kawamura H, Honda M, Takiguchi K, Kamiga T, Saito K, Muto A, Shiraso S, Yamashita N, Iwao T, Saji S, Kono K, Konno S. Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study. *Anticancer Research*. 202111; 41(11):5693-5702.

Honda M, Hori S, Kobayashi H, Hamada K, Kawamura H, Nakayama Y, Todate Y, Miyakawa T, Takano Y, Sato A, Konno S. Comparison of ethanol concentrations after drinking in patients who underwent total gastrectomy versus healthy controls. *ANZ Journal of Surgery*. 202107; 91(7-8):E474-E478.

Hamada K, Horikawa Y, Shiwa Y, Techigawara K, Nagahashi T, Fukushima D, Nishida S, Koyanagi R, Kawano K, Nishino N, Honda M. Clinical benefit of the multibending endoscope for gastric endoscopic submucosal dissection: a randomized controlled trial. *Endoscopy*. 202107; 53(7):683-690.

Nakayama Y, Kawamura H, Honda M, Takano Y, Takiguchi K, Kamiga T, Yamazaki S, Muto A, Shiraso S, Yamashita N, Iwao T, Kono K, Konno S. Benefit of intensive chemotherapy for elderly patients aged 80 years